Clinical Trial: Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Cancer
Study Type: INTERVENTIONAL
Official Title: A Multicenter, Open-label, Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Sol
Brief Summary:
This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment.Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens.Phase 1b will evaluate the safety and preliminary clinical activity of MBRC-101 at potential OBRDs.Phase 1 and Phase 1b will both characterize single and multiple-dose PK profiles and evaluate incidence and…
Read more